Kornimate/medical-research-clean huggingface dataset:
curcumin and piperine in reducing inflammation for ureteral stent-induced symptoms in patients with cancer

Conditions: Bladder Spasm; Malignant Neoplasm; Pain; Urinary Urgency

Summary: this pilot phase i trial studies the side effects and best dose of curcumin when given together with piperine (piperine extract \[standardized\]) in reducing inflammation for ureteral stent-induced symptoms in patients with cancer. curcumin is a spice similar to turmeric and works by decreasing the chemical moderators that produce inflammation in the body. piperine is pepper and works by increasing the amount of curcumin available in the body when taken with curcumin. giving curcumin together with piperine may reduce inflammation and discomfort from a ureteric stent in older patients with cancer.

primary objectives: i. to conduct a dose-escalation study with curcumin and piperine to derive a safe, optimal biological dose of this combination in cancer patients. secondary objectives: i. to describe the grade 2+ toxicities associated with curcumin and piperine. ii. to evaluate quality of life associated with this combination by means of the mayo modified urinary stent symptom questionnaire (ussq). tertiary objectives: i. to characterize the change in urinary prostaglandin e2 concentrations that occur at baseline and then after one week of curcumin + piperine. outline: this is a dose-escalation study of curcumin. patients receive curcumin orally (po) twice daily (bid) or thrice daily (tid) and piperine extract (standardized) po on days 1-7 in the absence of disease progression or unacceptable toxicity. after completion of study treatment, patients are followed up at 1 month.

Eligibility criteria:
inclusion criteria: * ureteral stent in place at study registration * patient reports pain, spasms, or urgency symptoms after stent placement, which are thought to be unrelated to other causes as per the patient or healthcare provider or both (documentation in the medical record is unnecessary) * ability to complete english language questionnaires by themselves or with assistance * after the week-long study treatment, participants must be willing to return to the enrolling institution for a follow-up visit * willingness to provide mandatory 24 hour urine collection samples for research purposes * able to swallow supplements * patient must have either a history of cancer or active cancer * registration \>= 7 days after placement of a new stent or \>= 3 days after a stent exchange * willingness to refrain from grapefruit juice for 7 days prior to and for 7 days during the study exclusion criteria: * receiving warfarin at registration * active cholecystitis * taking any of the following drugs at the time of study participation: epidermal growth factor receptor inhibitor, topoisomerase 1 inhibitor (camptothecin, irinotecan); buspirone, benzodiazepines, zolpidem, calcium channel blockers (such as felodipine, nifedipine, verapamil); digoxin or quinidine; codeine or fentanyl; phenytoin, propranolol, rifampin, or theophylline * history of alcohol abuse
implementation of work in progress (wip) sequences in magnetic resonance imaging (mri)

Conditions: Ischemic Cardiomyopathy; Nonischemic Cardiomyopathy

Summary: trial of new work in progress (wip) sequences in mri.


Eligibility criteria:
inclusion criteria: * clinical diagnosis of ischemic or non ischemic cardiomyopathy exclusion criteria: * claustrophobia * irregular heart rhythm

Keywords: myocardium magnetic resonance imaging
the lymphoid tissue pharmacology of antiretroviral drugs

Conditions: HIV Infection

Summary: hypothesis: antiretroviral drugs (arvs) with enhanced lt penetration characteristics in vitro and in macaques will translate into an arv regimen with increased ln and galt concentrations and a faster decay and more potent suppression of hiv replication in lt in hiv-infected persons. objectives: 1. determine lymph nodes (ln) and gut-associated lymphoid tissue (galt) pharmacokinetics (pk) in hiv-infected persons on an antiretroviral drug (arv) regimen. 2. determine virological responses of antiretroviral therapy in plasma, peripheral blood mononuclear cells (pbmcs) and lymphoid tissue (lt).

this is a single-center study of 18 arv naïve, hiv infected persons to assess impact of an arv regimen on lymph node (ln) and (galt) virus reservoirs. all participants will give informed consent. at baseline, plasma and pbmcs will be obtained and all subjects will have an incisional biopsy of an inguinal ln and pinch biopsy of ileum and rectum via colonoscopy. the selected lt-enhanced arv regimen will be initiated. participants will return to the clinic at weeks 2 and 4 and then monthly for safety evaluations, cd4 t cell counts, plasma hiv-rna and arv drug concentrations in plasma and pbmcs. an intensive pk study will be performed at week 2. at months 3 and 6, the inguinal ln biopsy and pinch biopsies of ileum and rectum will be repeated.

Eligibility criteria:
inclusion criteria: 1. antiretroviral drug (arv)-naive, hiv-infected individuals 2. aged 18 years or over 3. agree to initiating arv therapy 4. bmi ≤ 30 5. inguinal lymph node(s) identifiable by ultrasound at enrollment 6. screening plasma hiv rna \> 40,000 copies/ml 7. screening cd4 count \> 200 cells/mm3 8. women of child bearing potential must agree to use effective contraception while on the study. 9. screening viral isolates demonstrate genotype sensitivity to chosen antiretroviral therapy (art) regimen. 10. able to provide voluntary written consent exclusion criteria: 1. previous arv therapy 2. contraindications to arv regimen (e.g., comorbid conditions or drug interactions), or study procedures as determined by the principal investigator. 3. planning or current pregnancy or breastfeeding 4. history and/or presence of any clinically significant disease or disorder, such as cardiovascular, pulmonary, renal, hepatic, neurological, gastrointestinal and psychiatric/mental disease/disorder, which, in the opinion of the enrolling physician, may put the participant at risk because of participation in the study, influence the results of the study, or affect the participant's ability to participate in the study. 5. inability to comply with study procedures per enrolling physician discretion
acute phase response & periodontal treatment

Conditions: Periodontal Diseases

Summary: this study has compared quadrant scaling and root planing (q-srp) versus intensive treatment performed within 24 hours (fm-srp) in terms of acute phase responses following treatment of periodontal disease. the primary aim was to compare the differences in crp acute increase following fm-srp versus q-srp therapy (24 hours after therapy). secondary outcomes included changes in a broad array of inflammatory and endothelial injury markers between groups. patients were randomly assigned to either fm-srp and q-srp. data indicated that non-surgical periodontal therapy performed within 24 hours induced greater perturbations of systemic inflammation compared to conventional treatment.

aim. a moderate acute-phase response occurs 24 hours following full-mouth non-surgical treatment (fm-srp). aim of this study will be to compare quadrant scaling (q-srp) versus fm-srp in terms of systemic acute (24 hours) and medium-term (3 months) inflammation. material \& methods. 38 periodontitis-affected subjects will be randomly allocated to fm-srp or q-srp after a baseline visit. periodontal and anthropometric parameters, such as systolic and diastolic bood pressure, bmi and temperature, will be collected at baseline and 3 months. serum samples will be drawn at baseline, 1, 7 and 90 days after treatment. high sensitivity assays for a broad array of inflammatory (pcr, il-6, tnf-alpha) and endothelial assays will be performed.

Eligibility criteria:
inclusion criteria: * patients presenting with probing pocket depths (ppd) ≥5 mm, * bleeding on probing on at least 25% of their total sites * documented radiographic alveolar bone loss exclusion criteria: * age earlier than 18 and older than 70 years; * pregnant or lactating females; * females using contraceptive methods; * reported diagnosis of any systemic illnesses including cardiovascular, renal and liver diseases; * any pharmacological treatment within the 3 months before the beginning of the study; * pt in the previous 6 months.

Keywords: scaling and root planning c-reactive protein
prospective, multi-center, single-arm study to assess the safety of retrieval of the recovery g2 filter.

Conditions: Pulmonary Embolism; Venous Thromboembolic Disease

Summary: this study was designed to assess the safety of retrieval of the bard recovery® g2® filter system. the g2 filter is an fda-cleared device for inferior vena caval interruption in patients with pulmonary thromboembolism.


Eligibility criteria:
inclusion criteria: * the patient is at temporary , increased risk of pulmonary embolism requiring caval interruption exclusion criteria: * the patient has implanted filter in the ivc or superior vena cava (svc) * the patient has a duplicated or left-sided ivc * the patient has a known untreatable or uncontrollable malignancy * the patient has severe spinal deformity * the patient has a creatinine \> 2.0 mg/dl * the patient has a life expectancy of \< 6 months

Keywords: venous thromboembolic disease ivc filter pulmonary embolism
effect of occupational therapy at home e-rehabilitation (other) for persons post-stroke

Conditions: Stroke; eHealth; Occupational Therapy

Summary: the goal of this (cost)effectiveness study is to compare care as usual with other-intervention in cerebro vascular accident (cva) older adults in geriatric rehabilitation (gr). the main question\[s\] it aims to answer are: 1. what is the effectiveness of other, as compared to occupational therapy as usual (cau), on improving the self-perceived performance in daily activities of community-dwelling older persons post-stroke over a 24-week period after initiation of other or cau, as measured longitudinally (at week 4, 13 and 26)? secondary: 2. what is the effectiveness of other on improving satisfaction with the perceived daily performance of community-dwelling persons post-stroke, 26 weeks after start compared to usual ot? (quantitative approach) 3. what is the effectiveness of other on improving physical activity of community-dwelling persons post-stroke, 26 weeks after start compared to usual ot? (quantitative approach) 4. what is the effectiveness of other on improving self-management of community-dwelling persons post-stroke, 26 weeks after start compared to usual ot? (quantitative approach) 5. how do persons post-stroke and ot's experience and how do they reflect on other in supporting a sense of self-management, safety and improving daily functioning? (qualitative approach). 6. what factors influenced the intervention delivery and the perceived benefits in the other study (process evaluation)? 1) monitoring treatment fidelity, barriers and facilitators for implementation; 2) gain insight into the impact of other on the gr transition to home; 3) to gain insight into what stroke survivors and ot's think of other. 4) how participants, and professionals experience and thoughts they have on the other-intervention in supporting daily functioning and self-management cost-effectiveness 7. what is the cost-effectiveness of other on improving self-perceived performance in daily activities and quality adjusted life years (qalys) of community-dwelling persons post-stroke, 26 weeks after start compared to usual ot? (quantitative approach) participants will get the other-intervention treatment given by de occupational therapist which consists of activity monitoring, coaching and videoconferencing to optimalise the transition from clinical care to home. researchers will compare care as usual to see if there is a effect on improving the self-perceived performance in daily activities, self-management and improving physical activity .


Eligibility criteria:
inclusion criteria: * be able to walk a few steps with or without a walking device. * 60 years or older * an assessment score of at least 16 on the montreal cognitive assessment (moca) * an indication for follow up gr at home exclusion criteria: * who are terminally ill * who have severe aphasia; problems with understanding. * who has been assessed legally incapable by a geriatric doctor
efficacy and safety of iv diclofenac (div075v)for pain after elective orthopedic surgery

Conditions: Postoperative Pain

Summary: this study will compare repeated intermittent iv dosing of diclofenac in patient with moderate to severe post-surgical pain from elective orthopedic surgery.

the primary objective is to evaluate the analgesic efficacy and safety of three dosage levels of parenteral diclofenac in providing pain relief as compared to placebo or ketorolac tromethamine.

Eligibility criteria:
inclusion criteria: * scheduled within three weeks of the screening visit to undergo elective orthopedic surgery. * moderate to severe pain within 6 hours following completion of the required surgery. exclusion criteria: * chronic pain conditions. * chronic disease or recent cardiovascular events. * known allergy or hypersensitivity to the active compounds or any of the excipients used in the study.
impact of exogenous estrogens on cotisol levels during synacthen stimulation

Conditions: Adrenal Insufficiency; Hypogonadism Female

Summary: the aim is to investigate impact of exogenous estrogens on cotisol levels during synacthen stimulation in female hypogonal patients on estrogen substitution. both patients with and withour adrenal insufficiency will be studied

the aim is to investigate impact of exogenous estrogens on cotisol levels during synacthen stimulation in female hypogonal patients on estrogen substitution. both patients with and without adrenal insufficiency will be studied . all patients (inclusion criteria age 18-50 years, bmi \<35) will be followed for 6 months and have 3 synacthentests performed: one on transdermal estrogen (minimum 3 months), one on oral estrogens (min 3 months) and one without estrogen substitution for at least 3 months. primary endpoint is change in serum cortisol 30 minutes after synacthen stimulation

Eligibility criteria:
inclusion criteria: * hypogonadism * treatment with estrogen substitution exclusion criteria: * other formulations of glucocorticoid than oral hydrocortisone * pregnancy * bmi \> 35
a real-world study to gain clinical insights into roche ophthalmology products

Conditions: Neovascular Age-related Macular Degeneration; Diabetic Macular Edema; Retinal Vein Occlusion; Branch Retinal Vein Occlusion; Central Retinal Vein Occlusion; Hemi-retinal Vein Occlusion

Summary: the voyager study is a primary data collection, non-interventional, prospective, multinational, multicenter study. it is designed to collect real-world, long-term data to explore long-term effectiveness, safety, clinical insights, treatment patterns, and factors driving the treatment decisions among patients being treated with specified roche ophthalmology products in approved retinal indications (faricimab for neovascular age-related macular degeneration \[namd\], diabetic macular edema \[dme\], and retinal vein occlusion; port delivery system with ranibizumab for namd) in routine clinical practice. this study will not provide or make recommendations on use of any products including roche products; treatment decisions will be determined by the treating physician and must be made independently to the decision to participate in this study. participation in this study will not change or influence a patient's standard of care in any way.


Eligibility criteria:
inclusion criteria: 1. have provided informed consent, as required per local regulations 2.a) adult patient, as defined by local regulations and local product label, who is newly initiating treatment (or initiated treatment in the previous visit) with a specified approved roche ophthalmology product in retinal indication of interest for this study in at least one eye, according to the investigator's discretion in routine clinical practice; or 2.b) adult patient, as defined by local regulations and local product label, who is continuing treatment with any specified approved roche ophthalmology product in retinal indication of interest for this study in at least one eye after initiating that treatment in a roche interventional trial. exclusion criteria: 1. concomitant participation of the patient in an investigational ophthalmology clinical trial that includes receipt of any investigational drug or procedure within the last 28 days prior to enrollment (this restriction does not apply to patients who are rolling over from roche interventional studies and continuing treatment with any specified approved roche ophthalmology product in retinal indication of interest for this study)
mitral regurgitation in hypertrophic obstructive cardiomyopathy: fix it in a simple, effective and durable way!

Conditions: Hypertrophic Obstructive Cardiomyopathy; Mitral Regurgitation

Summary: septal myectomy is performed in selected cases to treat patients with hypertrophic obstructive cardiomyopathy (hocm). the mechanism that causes obstruction involves both the outflow tract itself and the mitral apparatus, with the appearance of mitral regurgitation (mr) by sam (systolic anterior motion). when the interventricular septum is not particularly thick, isolated myectomy may not be sufficient to eliminate the sam; in these cases the concomitant treatment of the mitral valve is considered. different approaches have been proposed: mitral replacement with prosthesis, plication or lengthening of the anterior leaflet or the edge-to-edge (ee) technique. in addition, a small proportion of patients with hocm may have mr from organic valve abnormalities, requiring specific treatment. currently, there are few studies in the literature aimed at determining the role of ee in the context of hocm; most of these studies are characterized by short follow-up or by the scarcity of echocardiographic data. the aim of the present study is to evaluate the long-term outcomes of ee associated with septal myectomy in patients with cmio, both from a clinical point of view and by reporting echocardiographic data.


Eligibility criteria:
inclusion criteria: * diagnosis of hocm with indication for surgery, * patients operated on from 2000 to 2017 * contextual diagnosis of mr needing reparative surgical treatment * age ≥ 18 years exclusion criteria: * hypertophic left ventricle due to other causes (aortic stenosis, arterial hypertension)
ketone supplementation in cystic fibrosis

Conditions: Cystic Fibrosis

Summary: this study will examine the effects of a novel ketone monester supplement on patients with cystic fibrosis experiencing an acute pulmonary exacerbation requiring hospitalization. patients will undergo standard testing along with blood sampling to examine concentrations of inflammatory markers. patients will then receive the ketone supplement for 5 days followed by post-testing to examine changes in pulmonary function and inflammatory markers

up to 25 hospitalized patients with cystic fibrosis will take part in this study at uab. patients will be randomly assigned to receive either an exogenous ketone or placebo supplement. participants will take the ketone or placebo for 5 days during hospitalization. participants will drink one 60 ml bottle twice daily of either the ketone or placebo. on day 1 and day 5, before the patient drinks the ketone (or placebo) the patient will be asked to fast overnight for 8 hours. following administration of the first morning dose of ketones (or placebo) blood samples will be obtained from a finger stick before (time 0 min) and following (15, 30, 60, 90, and 120 min) after they drink the supplement. a commercially available ketone meter (keto-mojo, napa, ca) that provides instant assessment of circulating ketone concentrations will be used to measure ketone concentrations in the blood. medical history history will be obtained at hospitalization. the study team will also examine the body for any abnormal signs and symptoms. sputum and blood will be collected prior to and following the ketone supplement or placebo. the hypothesis is that ketone supplementation will reduce inflammation via a well known inflammatory pathway to improve outcomes in patients with cystic fibrosis experiencing an acute pulmonary exacerbation

Eligibility criteria:
inclusion criteria: * diagnosis of cf * age \>19 * colonization with p. aeruginosa * acute pulmonary exacerbation requiring inpatient care exclusion criteria: * concurrent or recent (within 28 d of enrollment) use of corticosteroids * inability to produce sputum * acute respiratory failure * chronic liver or renal disease * pregnancy
retrospective study to evaluate the feasibility of ovarian preservation in patients with endometrial carcinoma

Conditions: Endometrial Cancer

Summary: endometrial cancer is one of the most common female malignancies in the united states, and has increased in incidence in taiwan in recent decades.a recent population-based analysis noted that 4% of endometrial cancers occurred in women aged 40 years or younger, furthermore it is up to 15% in taiwan according to the data of cancer registry. the standard treatment of endometrial cancer results in surgical menopause and places patients at risk for the long-term sequelae of estrogen deprivation. the goal of this study was to determine the frequency of a coexisting ovarian malignancy and to evaluate the outcome of ovarian preservation in women with treatment for endometrial cancer.

we reviewed the cases with early stage of endometrial cancer who have primary staging surgery between january 1989 to december 2009. the enrolled patients will be divided into two group (oophorectomy vs. ovary preservation) for analysis:the outcome and recurrence type.to evaluate the outcome of ovarian preservation in women with endometrial cancer .

Eligibility criteria:
inclusion criteria: * early stage endometrial cancer after primary surgery exclusion criteria: * mmmt, type 2 endometrial cancer

Keywords: ovarian preservation